Bionime Corporation is a Taiwan-based company principally engaged in the manufacture and distribution of blood glucose monitoring products. The Company's main products include blood glucose monitoring devices and blood glucose testing chips. Its products are applied in the testing and monitoring of blood glucose density. The Company distributes its products mainly to overseas markets, including Europe, Asia, the Americas and others.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
26-07-27	NT$57.30	+1.60%	56,316
26-07-24	NT$56.40	+1.81%	54,016
26-07-23	NT$55.40	-1.60%	66,098
26-07-22	NT$56.30	+0.90%	48,286
26-07-21	NT$55.80	+0.90%	50,101

End-of-day quote Taiwan S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Taiwan S.E. Other stock markets 2026-07-27			5-day change	1st Jan Change
57.30 ^TWD	+1.60%		+4.56%	-3.70%

07-13	Bionime Gets European Regulator's Certification for Glucose Monitoring System; Shares Jump 10%	MT
05-14	Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	4.43B 137M 121M 112M 103M 194M 13.16B 196M 1.33B 521M 6.49B 515M 504M 22.46B	P/E 2024	-31x	P/E 2025	-22.2x
Enterprise Value	7B 217M 191M 177M 163M 306M 20.8B 311M 2.11B 824M 10.26B 814M 797M 35.52B	EV / Sales 2024	3.48x	EV / Sales 2025	3.58x
Free-Float	53.01%	Yield 2024 *	-	Yield 2025	-

07-13	Bionime Gets European Regulator's Certification for Glucose Monitoring System; Shares Jump 10%	MT
05-14	Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-16	Bionime Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-13	Bionime Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-12	Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-17	Bionime Corporation Approves Amendment to the Article of Incorporation	CI
25-05-12	Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-10	Bionime Sees No Impact from US Reciprocal Tariffs	MT
24-11-12	Bionime Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-14	Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-08-08	Bionime Corporation Announces Financial Officer Changes	CI
24-06-28	Bionime Corporation Approves Cash Dividends, Payable on August 23, 2024	CI
24-05-10	Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

22-11-02	Bionime Announces the Introduction of Its Revolutionary iFree CGM for Diabetes Management Coming Soon	AQ
22-11-01	Bionime Corporation to Launch the Rightest iFree CGM, Proposed to Offer Precise and Accurate Blood Glucose Measurement and Monitoring	AQ
22-10-25	Bionime RIGHTEST iFree CGM System - An Innovative Approach to Keep Track of Every One Health	AQ
22-08-04	Bionime : Announcement of change the Globle Sales Division officer of the company.	PU
22-07-05	Bionime : Announcement of members of the first order audit committee of the Company.	PU

Bionime Corporation Stock

Stocks

4737

TW0004737002

Medical Equipment, Supplies & Distribution

Valuation: Bionime Corporation

Chart: Bionime Corporation

Latest news : Bionime Corporation

Press Releases: Bionime Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Bionime Corporation

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	+1.60%
1 week	+4.56%
Current month	+3.06%
1 month	+0.53%
3 months	-7.28%
6 months	+4.18%
Current year	-3.70%

1 week	54.8	57.3
1 month	54.8	69.9
Current year	49.75	72.9
1 year	49.75	73.9
3 years	43.14	81.92
5 years	43.14	88.92
10 years	40	88.92

Manager	Title	Age	Since
Chun Mu Huang CEO	Chief Executive Officer	-	2010-07-08
Hui Chen Chen DFI	Director of Finance/CFO	-	2017-11-05
Zhi Long Yeh CTO	Chief Tech/Sci/R&D Officer	-	2018-11-06

Director	Title	Age	Since
Chun Mu Huang CHM	Chairman	-	2003-04-13
Tai Hsiung Chiang BRD	Director/Board Member	-	2007-10-16
Chung Kai Tai BRD	Director/Board Member	-	2007-05-14

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIONIME CORPORATION	+1.60%	+4.56%	-16.19%	-15.75%	135M
GUARDANT HEALTH, INC.	-1.26%	-6.67%	+227.49%	+277.84%	19.54B
BIOMÉRIEUX	+1.14%	-3.15%	-43.58%	-26.61%	9.39B
LANTHEUS HOLDINGS, INC.	+3.06%	+0.41%	+48.13%	+28.50%	6.82B
10X GENOMICS, INC.	-0.76%	+4.98%	+225.44%	-24.40%	5.87B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-2.79%	+4.01%	-17.77%	-23.56%	5.61B
CARIS LIFE SCIENCES, INC.	+0.71%	-5.22%	-47.09%	-	4.39B
ANDON HEALTH CO., LTD.	+7.13%	-8.59%	+83.94%	+103.71%	4.19B
DIASORIN S.P.A.	+0.51%	-3.23%	-25.88%	-30.10%	4.03B
AUTOBIO DIAGNOSTICS CO., LTD.	+1.43%	-0.99%	-20.82%	-44.29%	2.66B
Average	+1.08%	-2.27%	+41.37%	+27.26%	6.26B
Weighted average by Cap.	+0.41%	-3.24%	+88.97%	+90.85%

	2024	2025
Net sales	1.93B 59.91M 52.63M 49.02M 45.01M 84.51M 5.75B 85.77M 582M 228M 2.83B 225M 220M 9.81B	1.84B 56.96M 50.04M 46.61M 42.79M 80.35M 5.46B 81.55M 554M 216M 2.69B 214M 209M 9.33B
Net income	-127M -3.94M -3.46M -3.22M -2.96M -5.56M -378M -5.64M -38.3M -14.97M -186M -14.79M -14.48M -645M	-180M -5.59M -4.91M -4.57M -4.2M -7.88M -536M -8M -54.27M -21.21M -264M -20.97M -20.51M -914M
Net Debt	2.78B 86.25M 75.77M 70.57M 64.8M 122M 8.27B 123M 838M 328M 4.08B 324M 317M 14.12B	2.57B 79.73M 70.05M 65.24M 59.9M 112M 7.65B 114M 775M 303M 3.77B 299M 293M 13.05B